Well, I just tested again, and LP(a) is down to 114.9 nmol/L. So 25% below what I assumed to be the baseline level of 156.
I was literally about to start Repatha and wanted to verify a return to ‘baseline’ so I could later test and see the actual net benefit. No idea what ‘baseline’ is now.
Are you also taking rapamycin? If so, did you track when the Lp(a) test was relative to the dose?
I’ve found that mine has ranged from 175 to 195 nmol/L depending on the day after the dose. In general, it was higher 7 days after the dose, while on day 4, it tended to be lower. At the same time, LDL-C was higher on day 4 and lower on day 7. It seems like the LDL-C and Lp(a) move in opposite directions as a function of time after a rapa dose, but I’ve never seen any studies on it.
Anyway, your Lp(a) is definitely high. If I could get in repatha, I would. Ezetimibe doesn’t affect it according to what I’ve read.
Yeah, unfortunately, it doesn’t mean that lowering the Lp(a) number translates into less MACE. It might just affect the biomarker, without affecting the outcomes. There are several agents that lower Lp(a), all with the same problem: aspirin, niacin, HRT, several others:
Do We Know When and How to Lower Lipoprotein(a)?
Therapeutic Lowering of Lipoprotein(a): A Role for Pharmacogenetics?